Sightera Biosciences is an AI drug discovery spin-off that trains its models on patient-derived biological material to design new small molecules for oncology and fibrosis.
| Date | Round | Amount |
|---|---|---|
| Jul 2026 | Pre Seed Antwerp-based Sightera Biosciences closed a 3 million euro pre-seed round to expand its patient-derived AI drug discovery platform and advance its lead molecular glue oncology programme. The company plans a larger round to take its lead program into clinical trials. | $3.2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.